The role of fibroblast growth factor-23 in cardiorenal syndrome

Nephron - Clinical Practice

Volumn 123, Issue 3-4, 2013, Pages 194-201

  Kovesdy, Csaba P ^a,b,c   Quarles, L Darryl ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Chronic kidney disease; Fibroblast growth factor 23; Physiology

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE;

ADVERSE OUTCOME; BLOOD VESSEL CALCIFICATION; BONE METABOLISM; CARDIORENAL SYNDROME; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HORMONE SYNTHESIS; HUMAN; HYPERPHOSPHATEMIA; INNATE IMMUNITY; ION TRANSPORT; MINERAL METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VITAMIN D METABOLISM;

CALCITRIOL; CARDIO-RENAL SYNDROME; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84889875899     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000353593     Document Type: Review

References (53)

1. Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP: Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 2010; 117:S10-S21.
2. Martin A, David V, Quarles LD: Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012; 92: 131-155.
3. Quarles LD: Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012; 318: 1040-1048.
4. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
5. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
6. Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, et al: Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966.
7. Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al: Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 2010; 107: 407-412.
8. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281: 15694-15700.
9. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y: Loss of Klotho contributes to kidney injury by derepression of Wnt/β-catenin signaling. J Am Soc Nephrol 2013; 24: 771-785.
10. Lindberg K, Olauson H, Amin R, Ponnusamy A, Goetz R, Taylor RF, et al: Arterial Klotho expression and FGF23 effects on vascular calcification and function. PLoS One 2013; 8:e60658.
11. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro OM, Mohammadi M, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
12. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, et al: Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178.
13. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T: Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218.
14. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, et al: Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007; 18: 2116-2124.
15. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al: Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315.
16. Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, et al: PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res 2011; 26: 1035-1046.
17. Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, et al: Fibroblast growth factor 23 production in bone is directly regulated by 1α,25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010; 299:F1212-F1217.
18. Martin A, Liu S, David V, Li H, Karydis A, Feng JQ, et al: Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011; 25: 2551-2562.
19. Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, et al: Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 584-591.
20. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM: Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011; 6: 383-389.
21. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM: FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004; 35: 455-462.
22. Kato K, Jeanneau C, Tarp MA, Benet-Pages A, Lorenz-Depiereux B, Bennett EP, et al: Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006; 281: 18370-18377.
23. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, et al: Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012; 27: 38-46.
24. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
25. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
26. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, et al: Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585.
27. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, et al: Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-487.
28. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD: Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353-361.
29. Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, et al: Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 2013; 8: 1009-1018.
30. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, et al: FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553.
31. Westerberg PA, Tivesten A, Karlsson MK, Mellstrom D, Orwoll E, Ohlsson C, et al: Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol 2013; 14: 85.
32. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.
33. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
34. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al: The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640-648.
35. Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE: FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 2012; 7: 2017-2022.
36. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
37. Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390.
38. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
39. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al: Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012; 7: 1155-1162.
40. Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, et al: Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012; 50: 1266-1274.
41. Xie J, Cha SK, An SW, Kuro OM, Birnbaumer L, Huang CL: Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun 2012; 3: 1238.
42. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al: Higher fibroblast growth factor-23 increases the risk of allcause and cardiovascular mortality in the community. Kidney Int 2013; 83: 160-166.
43. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, et al: A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012; 7:e44161.
44. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, et al: Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930.
45. Soriano S, Ojeda R, Rodriguez M, Almaden Y, Martin-Malo A, Aljama P: The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol 2013, E-pub ahead of print.
46. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, et al: Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339.
47. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, et al: Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011; 26: 2567-2571.
48. Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, et al: Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005; 9: 340-346.
49. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, et al: Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298:F1315-F1322.
50. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD: Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116.
51. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, et al: Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494.
52. Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, et al: Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 2013; 28: 899-911.
53. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, et al: Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 2009; 24: 1879-1888.